|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Small intestinal bacterial overgrowth in inactive Crohn's disease:Influence of thiopurine and biological treatment显示文摘AIM:To investigate the influence of thiopurines and biological drugs on the presence of small intestinal bacterial overgrowth(SIBO) in patients with inactive Crohn's disease(CD).METHODS:This was a prospective study in patients with CD in remission and without corticosteroid treatment,included consecutively from 2004 to 2010.SIBO was investigated using the hydrogen glucose breath test.RESULTS:One hundred and seven patients with CD in remission were included.Almost 58%of patients used maintenance immunosuppressant therapy and 19.6%used biological therapy.The prevalence of SIBO was16.8%.No association was observed between SIBO and the use of thiopurine Immunosuppressant(12/62patients),administration of biological drugs(2/21 patients),or with double treatment with an anti-tumor necrosis factor drugs plus thiopurine(1/13 patients).Half of the patients had symptoms that were suggestive of SIBO,though meteorism was the only symptom that was significantly associated with the presence of SIBO on univariate analysis(P<0.05).Multivariate analysis revealed that the presence of meteorism and a fistulizing pattern were associated with the presence of SIBO(P<0.05).CONCLUSION:Immunosuppressants and/or biological drugs do not induce SIBO in inactive CD.Fistulizing disease pattern and meteorism are associated with SIBO. | Cristina Sánchez-Montes Vicente Ortiz Guillermo Bastida Ester Rodríguez María Yago Belén Beltrán Mariam Aguas Marisa Iborra Vicente Garrigues Julio Ponce Pilar Nos | 2014 | World Journal of Gastroenterology2014，20，38： | 4 |
| 2 | Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients显示文摘AIM:To evaluate the effectiveness of adalimumab in preventing recurrence after intestinal resection for Crohn's disease in high-risk patients.METHODS:A multicenter,prospective,observational study was conducted from June 2009 until June 2010.We consecutively included high-risk Crohn's disease patients who had undergone an ileal/ileocolonic resection.High-risk patients were defined as two or more criteria:smokers,penetrating pattern,one or more previous surgical resections or prior extensive resection.Subcutaneous adalimumab was administered 2 wk(± 5 d) after surgery at a dose of 40 mg eow,with an initial induction dose of 160/80 mg at weeks 0 and 2.Demographic data,previous and concomitant treatments(antibiotics,5-aminosalicylates,corticosteroids,immunomodulators or biologic therapies),smoking status at the time of diagnosis and after the index operation and number of previous resections(type and reason for surgery) were all recorded.Biological status was assessed with C-reactive protein,erythrocyte sedimentation rate and fecal calprotectin.One year(± 3 mo) after surgery,an ileocolonoscopy and/or magnetic resonance enterography was performed.Endoscopic recurrence was defined as Rutgeerts score ≥ i2.Morphological recurrence was based on magnetic resonance(MR) score ≥ MR1.RESULTS:Twenty-nine patients(55.2% males,48.3% smokers at diagnosis and 13.8% after the index operation),mean age 42.3 years and mean duration of the disease 13.8 years were included in the study.A mean of 1.76(range:1-4) resections previous to adalimumab administration and in 37.9% was considered extensive resection.51.7% had previously received infliximab.Immunomodulators were given concomitantly to 17.2% of patients.Four of the 29(13.7%) developed clinical recurrence,6/29(20.7%) endoscopic recurrence and 7/19(36.8%) morphological recurrence after 1-year.All patients with clinical recurrence showed endoscopic and morphological recurrence.A high degree of concordance was found between clinical-endoscopic recurrence(k = 0.76,P < 0.001) and clinical-morphological recurrence(k = 0.63,P = 0.003).Correlation between endoscopic and radiological findings was good(comparing the 5-point Rutgeerts score with the 4-point MR score,a score of i4 was classified as MR3,i3 as MR2,and i2-i1 as MR1)(P < 0.001,r s = 0.825).During follow-up,five(17.2%) patients needed adalimumab dose intensification(40 mg/wk);Mean time to intensification after the introduction of adalimumab treatment was 8 mo(range:5 to 11 mo).In three cases(10.3%),a biological change was needed due to a worsening of the disease after the dose intensification to 40 mg/wk.One patient suffered an adverse event.CONCLUSION:Adalimumab seems to be effective and safe in preventing postoperative recurrence in a selected group of patients who had undergone an intestinal resection for their CD. | Mariam Aguas Guillermo Bastida Elena Cerrillo Belén Beltrán Marisa Iborra Cristina Sánchez-Montes Fernando Muoz Jesús Barrio Sabino Riestra Pilar Nos | 2012 | World Journal of Gastroenterology2012，18，32： | 3 |
| 3 | Genotypic differences in polyembryo formation and somatic embryogenesis increment in wheat (Triticum aestivum L.), following 2,4-D treatment显示文摘 | Rosario Linacero Marisa G. López-Bilbao Concepción Romero David A. Laurie Ana M. Vázquez | 1996 | Euphytica1996，，3： | 1 |
| 4 | Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients 显示文摘 | MARISA N ANURADHA K MARTINA L | 2006 | Gynecologic Oncology2006，103，2： | 1 |
| 5 | Preparation and characterisation of ibuprofen-poloxamer 188 granules obtained by melt granulation显示文摘 | Passerini N Albertini B Marisa L | 2002 | Eur J Pharm Sci2002，15，2： | 1 |
| 6 | Electrokineac enhancement of phenanthren biodegradation in creosote-polluted day soil显示文摘 | JOSE-LUIS N A MARISA B M ROSA P B | 2006 | Environmental Pollution2006，142，： | 1 |
| 7 | The effect of addition of different elastomers upon the crystalline nature of PP 显示文摘 | Silva A L N Marisa C G Lopes R | 2001 | J Appl Polym Sci2001，81，14： | 1 |
| 8 | The substance P/neurokinin-1 receptor system in lung cancer: Focus on the antitumor action of neurokinin-1 receptor antagonists显示文摘 | Miguel Mu?oz Ana González-Ortega Marisa Rosso María José Robles-Frias Andres Carranza Manuel Vicente Salinas-Martín Rafael Cove?as | 2012 | Peptides2012，，2： | 1 |
| 9 | Neonatal Hear-ing Screening : Failures, hearing loss and risk indicators显示文摘 | Raquel M O Marisa F A Amelia M N | 2011 | Braz J Otorhinolaryngol2011，，6： | 1 |
| 10 | Myelodysplastic syndromes: an update on molecular pathology显示文摘 | Mar Tormo Isabel Marugán Marisa Calabuig | 2010 | Clinical and Translational Oncology2010，，10： | 1 |
| 11 | Factors implicated in the generation and persistence of long-lived plasma cell-mediated autoimmunity显示文摘 | Marisa N José DA | | 0，，07： | 1 |
| 12 | Clinical applicability and prognostic significance of molecular response assessed by fluorescent‐ PCR of immunoglobulin genes in multiple myeloma. Results from a GEM / PETHEMA study显示文摘 | Joaquin Martinez‐Lopez Elena Fernández‐Redondo Ramón García‐Sánz María Angeles Montalbán Pilar Martínez‐Sánchez Bruno Pavia María Victoria Mateos Laura Rosi?ol Marisa Martín Rosa Ayala Rafael Martínez María Jesus Blanchard Adrian Alegre Joan Besalduch Joa | 2013 | Br J Haematol2013，，5： | 1 |
| 13 | Electrokinetic enhancement of phenanthrene biodegradation in creosote-polluted clay soil显示文摘 | Jose-Luis N A Marisa B M Rosa P B | 2006 | Environmental Pollution2006，142，： | 1 |
| 14 | Study of rheological behavior of elastomer/polypropyleneblends显示文摘 | Ana Lfleia N SiIv a Marisa C G Rocha Fernanda MBCoutinho | 2002 | Polymer Testing2002，21，3： | 1 |
| 15 | Adsorption of heavy metal cations using coal fly ash modified by hydrothermal method 显示文摘 | Marisa N Paulo S M S Vicente P S | 2009 | Fuel2009，88，9： | 1 |
| 16 | Paraneoplastic hyperinsulinism and secondary hypoglycaemia in a patient with advanced colon cancer: A rare association显示文摘We review the case of a 74-year-old patient with ad-vanced colon cancer who suffered recurrent bouts of hypoglycemia. A state of inappropriate, non-suppressed hyperinsulinism in the presence of severe hypoglycemia was diagnosed. We finally discuss the known mecha-nisms behind fasting hypoglycemia in patients with ad-vanced cancer, the diagnosis, and possible treatments of this rare paraneoplastic endocrine complication. | Roberto Díaz Jorge Aparicio Andrea Mendizábal Marisa Faus Tania Fleitas Francisco Aparisi Maria Martín | 2008 | World Journal of Gastroenterology2008，14，12： | 1 |
| 17 | Childhood abuse and neglect and cognitive flexibility in adolescents显示文摘 | Marisa N Linda C Jessica H | 2012 | Child Neuropsychol2012，18，2： | 1 |
| 18 | Adsorption of heavy metal cations using coal fly ash modified by hydrothermal method显示文摘 | Marisa N Paulo Sergio M S Vicente P D S | 2009 | Fuel2009，88，： | 1 |
| 19 | Outbreak of Extensively Drug-Resistant Acinetobacter baumannii Indigo-Pigmented Strains显示文摘 | Elisabet Vilacoba Marisa Almuzara Lucia Gulone Rocio Rodriguez Elida Pallone Romina Bakai Daniela Centrón María Soledad Ramírez | 2013 | Journal of Clinical Microbiology2013，，11： | 1 |
| 20 | Twelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipients显示文摘AIM: To determine the clinical reasons for conversion to everolimus(EVL) and long-term outcomes in heart transplant(HT) recipients.METHODS: A retrospective 12-mo study has been carried out in 14 Spanish centres to assess the efficacy and safety of conversion to EVL in maintenance HT recipients.RESULTS: Two hundred and twenty-two patients were included(mean age: 53 ± 10.5 years; mean time from HT: 8.1 ± 4.5 years). The most common reasons for conversion were nephrotoxicity(30%), chronic allograft vasculopathy(20%) and neoplasms(17%). The doses and mean levels of EVL at baseline(conversion to EVL) and after one year were 1.3 ± 0.3 and 1.2 ± 0.6 mg/d and 6.4 ± 3.4 and 5.6 ± 2.5 ng/mL, respectively. The percentage of patients receiving calcineurin inhibitors(CNIs) at baseline and on the final visit was 95% and 65%, respectively. The doses and mean levels of CNIs decreased between baseline and month 12 from 142.2 ± 51.6 to 98.0 ± 39.4 mg/d(P < 0.001) and from 126.1 ± 50.9 to 89.2 ± 47.7 ng/mL(P < 0.001), respectively, for cyclosporine, and from 2.9 ± 1.8 to 2.6 ± 1.9 mg/d and from 8.3 ± 4.0 to 6.5 ± 2.7 ng/mL(P = 0.011) for tacrolimus. In the subgroup of patients converted because of nephrotoxicity, creatinine clearance increased from 34.9 ± 10.1 to 40.4 ± 14.4 mL/min(P < 0.001). There were 37 episodes of acute rejection in 24 patients(11%). The most frequent adverse events were oedemas(12%), infections(9%) and gastrointestinal problems(6%). EVL was suspended in 44 patients(20%). Since the database was closed at the end of the study, no further followup data is available.CONCLUSION: Conversion to EVL in maintenance HT recipients allowed minimisation or suspension of the CNIs, with improved kidney function in the patients with nephrotoxicity, after 12 mo. | Nicolás Manito Juan F Delgado María G Crespo-Leiro José María Arizón Javier Segovia Francisco González-Vílchez Sònia Mirabet Ernesto Lage Domingo Pascual-Figal Beatriz Díaz Jesús Palomo Gregorio Rábago Marisa Sanz Teresa Blasco Eulàlia Roig | 2015 | World Journal of Transplantation2015，5，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员